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Electrodermal activity (EDA) and electrodermal biofeedback, when integrated with
pharmacologic treatments, indicate promising methods for the treatment of grand mal
seizures. They can be used to monitor patient arousal and help patients learn new
strategies to better cope with stress and anxiety. Our proposed method can possibly
reduce the number of crises for patients who are dependent on pharmacologic therapy
and can improve their quality of life. This article describes the scientific background of
electrodermal monitoring and electrodermal biofeedback for patients affected by grand
mal seizures. In this study, we have reported a clinical case study. The patient was treated
for 2 years with electrodermal biofeedback to augment pharmacologic treatments. The
trial has been designed in accordance with “n = 1 case study research”. Our results have
shown that our methods could achieve a significant reduction in grand mal seizures and
sympathetic arousal when applied. The patient under consideration was also relaxed
and exhibited greater competency to cope with stress. Additionally, the patient’s sense
of mastery and self-efficacy was enhanced.
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Introduction
Electrodermal activity (EDA) is a biological parameter that offers information about the
psychological condition of an individual (Prokasy and Raskin, 1973). It reflects the level of
functioning of sweat glands that are linked to the dynamic processes of the central and peripheral
nervous systems (Scrimali, 2012).
The human brain has many different modules and cortical areas, involved in EDA control, but
the data currently remains incomplete (Boucsein, 1992). Table 1 depicts the general picture today
(Wang, 1964; Sequeira and Roy, 1993).
Generally, EDA ismeasured by applying two electrodes to the palmar surface of the fingertips.We
also describe some alternate electrode placement for recording EDA (Boucsein, 1992) and, further,
more alternate methods for acquiring electrodermal data are reported. These alternate methods
are as follows: endosomatic recording without the application of an external current, exosomatic
recording with direct current, and exosomatic recording with alternating current (Boucsein et al.,
2012).
We have chosen placements that involve the volar surfaces of the distal phalanges. The apparatus
we used, (MindLAB Set by Psychotech) produces a small direct electrical current, (constant
voltage) between the two electrodes, that indicates EDA. EDA is considered as any change in the
conductance produced by any variation in sweat from an individual. In this case, exosomatic direct
current and constant voltage method have been adopted (Boucsein et al., 2012).
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TABLE 1 | Level and its corresponding module(s) and involved area(s).
Level Modules and Areas Involved
Cortical • Sensorimotor area
• Precentral motor cortex
• Brodmann area 6 of the temporal lobe
Striatal • Anterior limbic and infralimbic cortex
• Some parts of pallidum
• Caudate nucleus
Diencephalic • Dorsal thalamus
• Anterior hypothalamus
Mesencephalic • Lateral reticular formation of the midbrain
Rhomboencephalic • Roof nuclei of the cerebellum
• Ventromedial reticular formation of the midbrain
Spinal • A pool of sympathetic motoneurons controlling
sweating secretion in the spinal cord
Peripheral • A ganglion of the sympathetic chain
The potential is recorded between an area that is characterized
by many sweat glands and other areas that are characterized by
few sweat glands. This is known as an endosomaticmeasurement.
Both exosomatic and endosomatic activities are caused by sweat,
which is a salt solution. An increase in the levels of sweat for
an individual is indicated by an increase in the ions present on
the skin. The presence of many ions can increase the electric
conductance of the skin (Dawson et al., 2007).
In the field, generally speaking, exosomatic measurements are
used because they are easier to register. Currently, exosomatic
EDA is a well-documented psychophysiological parameter that
provides information about arousal, stress, and clinical anxiety
for various psychosomatic and psychiatric disorders (Prokasy
and Raskin, 1973).
Biofeedback uses an electronic apparatus to monitor (online)
the changes of some physiological functions in order to modify
and control these functions. The biofeedback settings represent
an individual’s interaction with the instrumentation (Khazan,
2013). Other variables are also included in the loop such as the
therapist, the environment, and the cognitive activities of the
patient. Biofeedback includes the following components: (1)
physiological parameters being measured; (2) electrodes; (3) a
transducer; (4) a differential amplifier; (5) an analysis unit that
can process biological signals; and (6) a display unit that can
produce auditory and visual feedback related to the measured
parameters. We have distinguished two types of visual display:
analog and digital.
Grand mal seizures are characterized by increased
sympathetic arousal (Nagai et al., 2004a). Therefore, biofeedback
for EDA is aimed at the reduction of this arousal, which can
be useful as part of an integrated approach for the treatment of
grand-mal seizures (Boon et al., 2001; Nagai et al., 2004b; Porges,
2011; Nagai and Trimble, 2014).
Materials and Method
We have conducted a single clinical case study in accordance
with the methodological principles adopted in n = 1 case study
research (McLeod, 2010).
A 33-year-old male patient who has been treated for 2 years
with electrodermal biofeedback and the number of crises has
been carefully monitored.
We carried out our research according to the laws and
regulations of our Country (Italy) as well as according to
any applicable international norms and standards, mainly the
Helsinki Declaration (World Medical Association, 2012). The
patient signed an informed consent form to participate in our
study. Our protocol was preliminarily revised and accepted
by the neurological staff of the Institution in charge of
curing the patient (a public Hospital). Neurologists recognized
that the proposed research cannot damage in any way the
patient and, on the contrary, that the use of electrodermal
biofeedback could be a positive change for bettering his clinical
condition.
The patient suffers from grand mal seizures and has been
treated with various antiepileptic drugs since he was 7 years
old. The diagnosis was confirmed using electroencephalographic
(EEG) evidence and brain mapping. The grand mal seizures
were referred to as a large malformation of the brain located
on the cortex of the right hemisphere of the patient. Since
the malformed area was too large, a treatment based on
surgery was not considered by neurosurgeons. In spite of his
adherence to pharmacologic treatment, the patient suffered
from crises during periods of increased stress and sympathetic
arousal. The patient reported that seizures were linked with
anxiety, interpersonal stress, and before a crisis, a headache
was frequently present. The patient used two medications:
carbamazepine (600 mg, twice a day) and lacosamide (200 mg,
twice a day).
The patient was treated, before our research, for many
years, with various and different protocols based on different
medications. The protocol that was used during our research also
showed the best results. For this reason, the Neurological staff
decided that it was not necessary to change medications for the
patient during our trial. The patient was treated at an outpatient
applied neuroscience unit that was set up in a private clinical
center known as the Centro Clinico ALETEIA.
We informed the patient that the treatment was experimental
and for this reason, we offered care for free. The patient came
each week for a 1 h sessions for a period of 2 years. During
these sessions, EDA as well as biofeedback trials were monitored.
In addition, problem-solving and coping strategies based on
cognitive and behavioral approaches were used.
The MindLAB Set system, produced by Psychotech, was
used. The set is composed of the hardware (Psychodata
Acquisition Unit), a pair of electrodes, and an interface device
for connection to a computer. Two integrated programs,
MindSCAN and Psychofeedback, were used to monitor and
record EDA (MindSCAN) as well as to conduct the weekly
biofeedback sessions (Psychofeedback).
For each session, the patient was asked to sit in a comfortable
Chaise Longue. The temperature in the laboratory was frequently
monitored and maintained at 22◦C in winter and 24◦C during
summer. A monitor and two speakers were positioned in front of
the patient for providing visual and acoustic feedback connected
with the Skin Conductance Level (SCL).
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FIGURE 1 | Results of research.
The patient was encouraged to ‘‘lower the arousal’’ by
acting on thinking, imagery, emotion, and somatic levels. The
patient was further encouraged to establish different kinds
of cognitive, emotional, and bodily-different attitudes. When
the graph of SCL was being drawn on the monitor and
reinforcement sounds were heard, the patient was encouraged
to understand and memorize the specific set realized in that
specific moment in his mind and body. On the contrary,
when both visual and acoustic feedback informed the patient
that the arousal was going up, he was trained to understand
the kind of negative attitude he was producing and then to
avoid it.
The patient developed an understanding and realization
of the coping strategy that are useful to reduce arousal.
Then he was encouraged to generalize this to real life
conditions. At the beginning of each session, before
practicing biofeedback, SCL was measured and the recorded
values were discussed together with the therapist. When
SCL was higher, i.e., when it indicated a warning sign of
stress, the patient was encouraged to find the reason for
it and was encouraged to try to reduce the stress. The
training was intuitive, comfortable, and interesting for the
patient.
Results
The average number of seizures over a 3-month period prior to
biofeedback training and cognitive and behavioral therapy was
5.3. This reported frequency had been essentially stable during
the last 6 months before the reported baseline (Figure 1).
During the following 2 years in which the patient took part in
weekly biofeedback treatments, the average number of seizures
was reduced to 0.75. The average SCL was 4.5 microsiemens
TABLE 2 | Number of seizures per month and the average values of SCL
(in microsiemens).
Baseline Biofeedback
Seizures per month (average values) 5.3 0.75
Average value of SCL (in microsiemens) 4.6 µS 2.1 µS
during the baseline period and 2.1 microsiemens during the
biofeedback treatment period (Table 2).
Table 2 shows the data that has been statistically analyzed
using Student t-tests. From our analysis, we found that t = 4.636
and p = 0.044. Therefore, the differences observed between the
values of the two studied parameters (the number of seizures and
the value of SCL expressed in microsiemens) measured before
and during the treatment are statistically significant.
Discussion
Our treatment, based on electrodermal biofeedback and applied
from the use of the MindLAB Set system that was integrated
into the pre-existing medication has indicated better outcomes
than just for the pharmacologic treatment for grand-mal seizures.
Since not much literature exists on seizure treatments that
integrate biofeedback with traditional pharmacologic treatment,
it was difficult to analyze our findings. Micoulaud-Franchi
et al. (2014) have underlined that the neurofeedback protocol
on sensorimotor rhythms (SMR) has been investigated in
many studies, while newer neurofeedback protocols on slow
cortical potential (SCP) and EDA-biofeedback protocols have
been used for just a few studies (Micoulaud-Franchi et al.,
2014).
The results of our research show that EDA biofeedback can
improve the treatment profile of people affected by grand mal
seizures. Moreover, the number of crisis per month, which
is the most clinical item, when treating seizures diminished
significantly.
Recently, Nagai (2014) suggested that seizure precipitation
could occur due to certain psychological factors such as
stress, anxiety, and depression. Our results show that EDA-
biofeedback can reduce arousal and improve mood. According
to Nagai (2014), EDA-biofeedback can improve thalamo-cortical
regulation of neural excitability across brain networks as it
focuses on the reduction of peripheral sympathetic tone.
The patient who participated in our study was more
relaxed and exhibited a greater competency in coping with
stress. In addition, the patient’s sense of mastery and self-
efficacy was enhanced. This observation during the patient’s
treatment could be an interesting future topic; however, this
has not been systematically investigated by using any specific
assessment instruments. Thus, further investigations are required
to examine how biofeedback, when successfully integrated with
pharmacologic treatments of grand mal seizures can improve
important psychological variables such as mastery, self-efficacy,
and self-esteem.
In conclusion, the use of EDA-biofeedback seems
to be an interesting treatment procedure compared to
Neurofeedback, with respect to costs and possibilities of
disseminating the treatment clinically. EDA-biofeedback
is inexpensive and can be put into practice without any
specific training. In terms of the cost of professional
devices for Neurofeedback and EDA-biofeedback, the
latter can be integrated into the treatment of grand mal
seizures before trying Neurofeedback, which is specific and
expensive.
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